Banaschewski Tobias, Coghill David, Santosh Paramala, Zuddas Alessandro, Asherson Philip, Buitelaar Jan, Danckaerts Marina, Döpfner Manfred, Faraone Stephen V, Rothenberger Aribert, Sergeant Joseph, Steinhausen Hans-Christoph, Sonuga-Barke Edmund J S, Taylor Eric
Dept. of Child & Adolescent Psychiatry/Psychotherapy, University of Goettingen, Von-Siebold-Str. 5, 37075 Goettingen, Germany.
Eur Child Adolesc Psychiatry. 2006 Dec;15(8):476-95. doi: 10.1007/s00787-006-0549-0. Epub 2006 May 5.
A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.
本文报道了一项关于使用长效药物治疗注意力缺陷多动障碍(ADHD)和多动障碍的已发表及未发表数据的系统评价,给出了缓释兴奋剂制剂和托莫西汀(ATX)的效应量和治疗人数。来自几个欧洲国家的专家小组利用该评价对这些药物在实际应用中的使用提出建议,并报告了结论:(1)应提供并使用长效制剂;(2)它们不应替代短效药物(由于成本和给药灵活性的原因,短效药物将是许多儿童的初始治疗药物)。需要个体化的临床选择。(3)ATX和兴奋剂的缓释制剂都应可供使用。选择将取决于具体情况,并给出了详细建议。